ToxiPharm LLC

ToxSignal

Clinical Toxicology Intelligence

Issue

#17

September 2026

A New Class of Synthetic Opioids Got Scheduled This Week. Your Panel Cannot Detect Them.

DEA placed four benzimidazolone-derived orphine-class synthetic opioids in Schedule I effective August 27: 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine, and spirochlorphine (FR 2026-17531). The action was proposed July 1 and finalized without modification.

These are not fentanyl analogs. They are not nitazenes. The orphine/chlorphine class has a benzimidazolone core, the same scaffold as brorphine, which appeared in the illicit supply several years ago. Nothing on a standard opioid immunoassay panel is designed to detect them, and LC-MS/MS confirmation is only useful if the compound is included in the instrument's target list. Most clinical laboratory menus do not carry orphine-class targets yet.

The CFSRE's NPS Discovery program had already flagged N-propionitrile chlorphine in over 100 forensic toxicology cases by January 2026, seven months before the final scheduling action. The detection gap preceded the legal response. Based on the pattern established with nitazenes, the lag between scheduling and routine laboratory detection in clinical settings will likely persist for 12 to 18 months per batch action.

DEA Proposed Rule / Sleep Medications

DEA Proposes Moving Three Sleep Medications from Schedule IV to V. Comments Close September 10.

DEA has proposed rescheduling suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq) from Schedule IV to Schedule V (FR 2026-16375). The rationale: low abuse potential relative to other Schedule IV substances and no demonstrated physical or psychological dependence. The dual orexin receptor antagonist (DORA) class works through a fundamentally different mechanism than benzodiazepines or Z-drugs; it blocks wakefulness-promoting orexin signals rather than enhancing GABA activity.

For OTP and addiction medicine settings, the timing is relevant. Insomnia in early methadone stabilization is a daily clinical problem, and the usual answers carry real respiratory-depression risk when stacked on methadone. A Schedule V DORA is materially easier to obtain than a benzodiazepine and does not carry the same respiratory-depression profile. If this rescheduling finalizes, it removes a prescribing friction point for a medication with a cleaner safety profile in this population.

Comment deadline: September 10, 2026  ·  FR 2026-16375

FDA / Reagan-Udall Foundation / Sept 9

FDA Public Meeting on Opioid Medications: Attendance and Written Comments Still Open.

FDA and the Reagan-Udall Foundation are holding a hybrid public meeting on opioid medications September 9, 12:30 to 4:30 p.m. ET, at FDA White Oak and virtually. The meeting is a statutory requirement under Section 112 of the SUPPORT for Patients and Communities Reauthorization Act of 2025, covering scientific evidence for conditions of use, safety, and benefit-risk of opioid medications for pain and addiction. The deadline to request to present passed August 27; virtual attendance and written comment remain open.

This is where the next round of opioid labeling and benefit-risk framing gets shaped. Whatever FDA signals here will eventually reach OTP patients.

R I Med J  ·  Case Report  ·  2026

Medetomidine Withdrawal Is Not Sedation. It Is a Refractory Hyperadrenergic Crisis. First Rhode Island Case.

Porto et al. describe a 30-year-old woman intubated for agitation and delirium who became progressively tachycardic and hypertensive despite maximal sedation. A comprehensive toxicology panel returned medetomidine. This is the first reported Rhode Island case. Medetomidine is an alpha-2 adrenergic agonist used in veterinary anesthesia; it acts as an adulterant in the illicit opioid supply in the same chemical space as xylazine. When it wears off, the withdrawal phenotype is the opposite of the acute effect: not sedation, but refractory sympathetic activation. Naloxone does not address it. A standard opioid panel does not detect it. PMID 42647839

CDC MMWR  ·  Surveillance Data  ·  August 2026

Buprenorphine Dispensing Rose Through 2021, Then Declined Through 2025. Rural Rates Stayed Higher Than Urban.

CDC's MMWR analysis (vol. 75, no. 33, August 27) found that buprenorphine dispensing rates rose nationally through 2021, then declined through 2025, while ED-administered buprenorphine rose and remained consistently lower in rural areas. The rural trend is notable: outpatient dispensing held up better in rural counties even as the national trend turned down. ED-initiated buprenorphine, which showed some of the strongest access equity data, remained a rural gap. The waiver requirement was eliminated in 2023, and the DEA buprenorphine telemedicine rules were made permanent, but the dispensing curve bent before those changes could have a full effect. The reversal in the national trend warrants tracking. MMWR 75(33)

From Bill

"The orphine class scheduling this week illustrates something I spend a lot of time explaining in consulting work: the DEA schedule and the laboratory panel are two separate systems tracking two different things. When a new class gets scheduled, programs often hear 'controlled substance' and assume their testing catches it. That assumption is almost always wrong for the first year or two. The answer is not to stop testing. It is to stop treating a negative result as evidence of abstinence when the clinical picture says otherwise, and to document that distinction in writing."

Dr. William Bundy Jr., PharmD  ·  ToxiPharm LLC

Tox Pearl #17 is out.

Medetomidine withdrawal presents as a refractory hyperadrenergic crisis, not sedation. Naloxone does not address it. A standard opioid panel does not detect it. This Pearl covers what to look for, why it is now a Virginia-corridor concern, and what a comprehensive panel adds to the clinical picture. Free one-page clinical reference at toxipharm.org.

Questions about a drug test result? Consulting on an OTP or drug court program?

Single-drug deep dives for frontline clinicians and testing programs.